Abstract | BACKGROUND AND PURPOSE: MATERIALS AND METHODS: We analyzed data prospectively collected in the Solitaire FR With Intention for Thrombectomy randomized clinical trial. A multivariable logistic regression model was used to identify independent clinical, imaging, and procedural predictors of any intracranial hemorrhage and of 7 intracranial hemorrhage subtypes. Univariate analysis was used to determine the impact of each of the intracranial hemorrhage subtypes on clinical outcome. RESULTS: Among the 144 enrolled patients, any radiologic intracranial hemorrhage (21.3% versus 38.2%, P = .035), symptomatic intracranial hemorrhage (1.1% versus 10.9%, P = .012), and subarachnoid hemorrhage (2.2% versus 12.7%, P = .027) occurred less frequently in the Solitaire FR than in the Merci retriever arms. The most common independent determinant of hemorrhage occurrence was rescue therapy with intra-arterial rtPA, which was associated with any intracranial hemorrhage and 4 subtypes and tended to be used more frequently in the Merci group (10.9% versus 3.4%; P = .09). Among the hemorrhage subtypes, basal ganglionic hemorrhage had the strongest impact on good clinical outcome at 90 days (OR, 0.30; P = .025) and was associated with higher reperfusion, prolonged time to treatment, and rescue therapy with intra-arterial rtPA. CONCLUSIONS:
|
Authors | R Raychev, R Jahan, D Liebeskind, W Clark, R G Nogueira, J Saver, SWIFT Trial Investigators |
Journal | AJNR. American journal of neuroradiology
(AJNR Am J Neuroradiol)
Vol. 36
Issue 12
Pg. 2303-7
(Dec 2015)
ISSN: 1936-959X [Electronic] United States |
PMID | 26316567
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | © 2015 by American Journal of Neuroradiology. |
Chemical References |
- Fibrinolytic Agents
- Tissue Plasminogen Activator
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Cerebral Hemorrhage
(epidemiology, etiology)
- Female
- Fibrinolytic Agents
(adverse effects)
- Humans
- Male
- Middle Aged
- Stroke
(drug therapy, surgery)
- Thrombectomy
(adverse effects, instrumentation, methods)
- Tissue Plasminogen Activator
(adverse effects)
- Treatment Outcome
|